News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Drugs RG1678 Show Promise Treating Schizophrenia, Blood Cancer in Mid-Stage Studies
December 6, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH Dec 6 (Reuters) - Swiss drugmaker Roche Holding AG (ROG.VX) presented the results of studies on two drugs in mid-stage development that may go some way towards addressing concerns about the strength of the company's drug pipeline.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
Roche
MORE ON THIS TOPIC
Pain
Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill
January 22, 2026
·
2 min read
·
Tristan Manalac
Insights
From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM
January 22, 2026
·
1 min read
·
Jennifer Smith-Parker
Insights
The New Gold Rush in Brain Science
January 22, 2026
·
5 min read
·
Jennifer Smith-Parker
Podcast
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
January 21, 2026
·
1 min read
·
Heather McKenzie
